Envestnet Asset Management
LYEL icon

Envestnet Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Envestnet Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,164
Closed -$80.8K – 4043
2022
Q4 		$80.8K Sell
1,164
-4
-0.3% -$397 ﹤0.01% 3837
2022
Q3 		$171K Buy
+1,168
New +$158K ﹤0.01% 3630

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Envestnet Asset Management's LYEL Position: Q1 2023 in Review

Envestnet Asset Management sold out of Lyell Immunopharma (LYEL) in Q1 2023, closing a stake of 1,164 shares — an estimated $80.8K sold.

Envestnet Asset Management first reported a position in LYEL in Q3 2022 and held it in 2 quarters. The position peaked at $171K in Q3 2022. 99 funds tracked by Wall St. Rank hold LYEL as of Q1 2023.

  • Envestnet Asset Management reported no remaining Lyell Immunopharma position as of Q1 2023 after selling out during the quarter.
  • Envestnet Asset Management sold 1,164 Lyell Immunopharma shares in Q1 2023, an estimated $80.8K.
  • Envestnet Asset Management first reported a position in Lyell Immunopharma in Q3 2022 and held it in 2 quarters.
  • Envestnet Asset Management's Lyell Immunopharma position peaked at $171K in Q3 2022.
  • 99 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2023.

Based on Envestnet Asset Management's 13F filing for Q1 2023, filed 11 May 2023.